Islet amyloid: A complication of islet dysfunction or an aetiological factor in Type 2 diabetes?

Diabetologia

Volumn 47, Issue 2, 2004, Pages 157-169

  Clark, A ^a   Nilsson, M R ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Amyloid; Diabetes; Fibrils; Islet; Islet amyloid polypeptide; Pathophysiology

Indexed keywords

AMYLIN; AMYLOID; INSULIN;

AMYLOIDOSIS; CELL DEATH; GENE IDENTIFICATION; GLUCOSE INTOLERANCE; GLYCATION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SYNTHESIS; MICROFILAMENT; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS AMYLOIDOSIS; PANCREAS DISEASE; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; REVIEW;

AMINO ACID SEQUENCE; AMYLOID; AMYLOIDOSIS; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; GLYCOSYLATION; HUMANS; ISLETS OF LANGERHANS; MICROSCOPY, ELECTRON; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; PROINSULIN; PROTEIN CONFORMATION; PROTEIN PRECURSORS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 1542375103     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1304-4     Document Type: Review

References (129)

1. Schneider HM, Storkel S, Will W (1980) Das Amyloid der Langerhansschen Inseln und seine Beziehung zum Diabetes mellitus. Dtsch Med Wochenschr 105:1143-1147
2. Röcken C, Linke RP, Saeger W (1992) Immunohistology of islet amyloid polypeptide in diabetes mellitus: semi-quantitative studies in a post-mortem series. Virchows Arch A Pathol Anat Histopathol 421:339-344
3. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC (1988) Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res Clin Prac 9:151-159
4. Opie E (1901) The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J Exp Med 5:527-540
5. Cecil RL (1909) A study of the pathological anatomy of the pancreas in ninety cases of diabetes mellitus. J Exp Med 11:266-290
6. Ehrlich J, Ratner M (1961) Amyloidosis of the islets of Langerhans. A restudy of islet hyaline in diabetic and non-diabetic individuals. Am J Pathol 38:49-59
7. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electro-physiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876-8884
8. Heitner J, Dickson D (1997) Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49:1306-1311
9. Bruce DG, Harrington N, Davis WA, Davis TM (2001) Dementia and its associations in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 53:165-172
10. Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253
11. Westermark P (1994) Amyloid and polypeptide hormones: what is their interrelationship? Int J Exp Clin Invest 1:47-60
12. Lorenzo A, Razzaboni B, Weir G, Yankner B (1994) Pancreatic islet cell toxicity of amylin associated with Type-2 diabetes mellitus. Nature 368:756-760
13. Janciauskiene S, Ahrén B (1998) Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. Biochem Biophys Res Commun 251:888-893
14. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, Nanjo K (1991) Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 129-132
15. Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK, Rizza RA (1990) Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39:752-756
16. Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW, Boyko EJ, Schwartz RS, Newell-Morris L, Fujimoto WY (1998) Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47:640-645
17. Sanke T, Bell GI, Sample C, Rubenstein AH, Steiner DF (1988) An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem 263:17243-17246
18. Badman MK, Shennan KI, Jermany JL, Docherty K, Clark A (1996) Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378:227-231
19. Higham. CE, Hull RL, Lawrie L, Shennan KIJ, Morris JF, Birch NP, Docherty K, Clark A (2000) Processing of synthetic pro-islet amyloid polypeptide (proIAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267:4998-5004
20. Hutton JC (1994) Insulin secretory granule biogenesis and the proinsulin-processing endopeptidases. Diabetologia 37 [Suppl 2]:S48-56
21. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R (1994) Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37:188-194
22. Jaikaran ETAS, Clark A (2001) Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 1537:179-203
23. Koning EJ de, Bodkin NL, Hansen BC, Clark A (1993) Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia 36:378-384
24. Howard C (1978) Insular amyloidosis and diabetes mellitus in Macaca nigra. Diabetes 27:357-364
25. O'Brien T, Hayden D, Johnson K, Fletcher T (1986) Immuno-histochemical morphometry of pancreatic endocrine cells in diabetic normoglycaemic glucose-intolerant and normal cats. J Comp Pathol 96:357-369
26. Betsholtz C, Christmansson L, Engström U, Rorsman F, Svensson V, Johnson KH, Westermark P (1989) Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett 251:261-264
27. Westermark P, Engström U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide - pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036-5040
28. Moriarty DF, Raleigh DP (1999) Effects of sequential proline substitutions on amyloid formation by human amylin (20-29). Biochemistry 38:1811-1818
29. Green J, Goldsbury C, Mini T, Sunderji S, Frey P, Kistler J, Cooper G, Aebi U (2003) Full-length rat amylin forms fibrils following substitution of single residues from human amylin. J Mol Biol 326:1147-1156
30. Roberts A, Leighton B, Todd J, Cockburn D, Schofield P, Sutton R, Holt S, Boyd Y, Day A, Foot E, et al. (1989) Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci USA 86:9662-9666
31. Bushfield M, Savage A, Morris NJ, Houslay MD (1993) A mnemonical or negative-co-operativity model for the activation of adenylate cyclase by a common G-protein-coupled calcitonin-gene-related neuropeptide (CGRP)/amylin receptor. Biochem J 293:229-236
32. Bhogal R, Smith DM, Bloom SR (1992) Investigation and characterisation of binding sites for islet amyloid polypeptide in rat membranes. Endocrinology 130:906-913
33. Zumpe ET, Tilakaratne N, Fraser NJ, Christopoulos G, Foord SM, Sexton PM (2000) Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem Biophys Res Commun 267:368-372
34. Clark A, Cooper GJ, Lewis CE, Morris JF, Willis AC, Reid KB, Turner RC (1987) Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 2:231-234
35. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881-3885
36. Gebre-Medhin S, Olofsson C, Mulder H (2000) Islet amyloid polypeptide in the islets of Langerhans: friend or foe? Diabetologia 43:687-695
37. Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Tornell J, Westermark P, Sundler F, Ahrén B, Betsholtz C (1998) Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250:271-277
38. Ahrén B, Oösterwijk C, Lips CJ, Höppener JW (1998) Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. Diabetologia 41:1374-1380
39. Maloy AL, Longnecker DS, Greenberg ER (1981) The relation of islet amyloid to the clinical type of diabetes. Hum Pathol 12:917-922
40. Clark A, Holman R, Matthews D, Hockaday T, Turner R (1984) Non-uniform distribution of islet amyloid in the pancreas of 'maturity-onset' diabetic patients. Diabetologia 27:527-528
41. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254-259
42. Chargé SB, Esiri MM, Bethune CA, Hansen BC, Clark A (1996) Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. J Pathol 179:443-447
43. Snow AD, Willmer J, Kisilevsky R (1987) Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab Invest 56:120-123
44. Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238
45. Rochet JC, Lansbury PT Jr (2000) Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10:60-68
46. Higham CE, Jaikaran ETAS, Fraser PE, Gross M, Clark A (2000) Preparation of synthetic human islet amyloid polypaptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Letts 470:55-60
47. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC (1996) Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes 45:1094-1101
48. Westermark P, Eizirik DL, Pipeleers DG, Hellerström C, Andersson A (1995) Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia 38:543-549
49. Koning EJ de, Morris ER, Hofhuis FM, Posthuma G, Hoppener JW, Morris JF, Capel PJ, Clark A, Verbeek JS (1994) Intra-and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 91:8467-8471
50. Kayed R, Bernhagen J, Greenfield N, Sweimeh K, Brunner H, Voelter W, Kapurniotu A (1999) Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. J Mol Biol 287:781-796
51. Goldsbury C, Kistler J, Aebi U, Arvinte T, Cooper GJ (1999) Watching amyloid fibrils grow by time-lapse atomic force microscopy. J Mol Biol 285:33-39
52. Nishi M, Sanke T, Nagamatsu S, Bell GI, Steiner DF (1990) Islet amyloid polypeptide. A new b-cell secretory product related to islet amyloid deposits. J Biol Chem 265:4173-4176
53. Hutton JC (1984) Secretory granules. Experientia 40:1091-1098
54. Janciauskiene S, Eriksson S, Carlemalm E, Ahren B (1997) 15 cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Biochem Biophys Res Commun 236:580-585
55. Westermark P, Li ZC, Westermark GT, Leckstrom A, Steiner DF (1996) Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379:203-206
56. Jaikaran ETAS, Nilsson MR, Clark A (2003) Pancreatic b-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem J Oct 20 (epublication)
57. Larson JL, Ko E, Miranker AD (2000) Direct measurement of islet amyloid polypeptide fibrillogenesis by mass spectrometry. Protein Sci 9:427-431
58. Jaikaran ETAS, Higham CE, Serpell LC, Zurdo J, Gross M, Clark A, Fraser PE (2001) Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J Mol Biol 308:515-525
59. Serpell LC, Sunde M, Blake CCF (1997) The molecular basis of amyloidosis. Cell Mol Life Sci 53:871-887
60. Nilsson MR, Driscoll M, Raleigh DP (2002) Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation. Protein Sci 11:342-349
61. Nishi M, Bell GI, Steiner DF (1990) Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin- dependent) diabetic patients. Diabetologia 33:628-630
62. Cook JT, Patel PP, Clark A, Hoppener JW, Lips CJ, Mosselman S, O'Rahilly S, Page RC, Wainscoat JS, Turner RC (1991) Non-linkage of the islet amyloid polypeptide gene with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34:103-108
63. Seino S (2001) S20G mutation of the amylin gene is associated with Type II diabetes in Japanese. study group of comprehensive analysis of genetic factors in diabetes mellitus. Diabetologia 44:906-909
64. Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S, Kumagaye KY, Nakajima K, Nanjo K (1996) Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 45:1279-1281
65. Lee SC, Hashim Y, Li JKY, Ko GTC, Critchley JAJH, Cockram CS, Chan JCN (2001) The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: evidence for associations with type 2 diabetes and cholesterol levels. Clin Endocrinol 54:541-546
66. Birch CL, Fagan LJ, Armstrong MJ, Turnbull DM, Walker M (1997) The S20G islet-associated polypeptide gene mutation in familial NIDDM (Letter). Diabetologia 40:1113
67. Yamada K, Yuan X, Ishiyama S, Nonaka K (1998) Glucose tolerance in Japanese subjects with S20G mutation of the amylin gene. Diabetologia 41:125
68. Westermark P, Ma Z, Gustavsson A, Westermark GT, Engström U, Sakagashira S, Sanke T, Nanjo K (1998) Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. In: Kyle RA, Gertz MA (eds) Amyloid and amyloidosis. Proceedings of the VIIIth International Symposium on Amyloidosis. Parthenon, New York, pp 551-553
69. Sakagashira S, Hiddinga HJ, Tateishi K, Sanke T, Hanabusa T, Nanjo K, Eberhardt NL (2000) S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. Am J Pathol 157:2101-2109
70. Novials A, Rojas I, Casamitjana R, Usac EF, Gomis R (2001) A novel mutation in islet amyloid polypeptide (IAPP) gene promoter is associated with Type II diabetes mellitus. Diabetologia 44:1064-1065
71. Clark A, Matthews DR, Naylor BA, Wells CA, Hosker JP, Turner RC (1987) Pancreatic islet amyloid and elevated proinsulin secretion in familial maturity-onset diabetes. Diabetes Res Clin Prac 4:51-55
72. Porte D, Kahn SE (1989) Hyperproinsulinaemia and amyloid in NIDDM: clues to etiology of islet beta-cell dysfunction. Diabetes 38:1333-1336
73. Halban PA, Kahn SE (1997) Release of incompletely processed proinsulin is the cause of the disproportionate proinsulineamia of NIDDM. Diabetes 46:1725-1732
74. Hou X, Ling Z, Quartier E, Foriers A, Schuit F, Pipeleers D, Van Schravendijk C (1999) Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia 42:188-194
75. Westermark GT, Steiner DF, Gebre-Medhin S, Engström U, Westermark P (2000) Pro islet amyloid polypeptide (proIAPP) immunoreactivity in the islets of Langerhans. Uppsala J Med Sci 105:97-106
76. Wang J, Xu J, Finnerty J, Furuta M, Steiner DF, Verchere CB (2001) The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes 50:534-539
77. Krampert M, Bernhagen J, Schmucker J, Horn A, Schmauder A, Brunner H, Voelter W, Kapurniotu A (2000) Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP). Chem Biol 7:855-871
78. Park K, Verchere CB (2000) Identification of a heparin-binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide: implications for islet amyloid formation. J Biol Chem 276:16611-16616
79. Potter-Perigo S, Hull RL, Tsoi C, Braun KR, Andrikopoulos S, Teague J, Verchere CB, Kahn SE Wight TN (2003) Proteoglycans synthesized and secreted by pancreatic islet beta-cells bind amylin. Arch Biochem Biophys 413:182-190
80. Furth AJ (1997) Glycated proteins in diabetes. Br J Biomed Sci 54:192-200
81. McKillop AM, Mooney MH, Harriott P, Flatt PR, O'Harte FP (2001) Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay. Biochem Biophys Res Commun 286:524-528
82. Kapourniotu A, Bernhagen J, Greenfield N, Al-Abed Y, Teichberg S, Frank RW, Voelter W, Bucala R (1998) Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. Eur J Biochem 251:208-216
83. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643-651
84. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Tosgiori H, Matsukara S (1992) Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 15:97-102
85. German MS, Moss LG, Wang J, Rutter WJ (1992) The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes. Mol Cell Biol 12:1777-1788
86. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R (1991) Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34:52-54
87. Jorgensen JO, Rosenfalck AM, Fisker S, Nyholm B, Fineman MS, Schmitz O, Madsbad S, Holst JJ, Christiansen JS (2000) Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study. Eur J Endocrinol 143:593-599
88. Mulder H, Ahrén B, Stridsberg M, Sundler F (1995) Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 38:395-402
89. O'Brien TD, Westermark P, Johnson KH (1991) Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 40:1701-1706
90. Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R (1993) Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36:84-87
91. Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisser-man JA, Westermark GT, Leckstrom A, Westermark P, Steiner DF (1993) Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett 323:40-44
92. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW (1994) Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457-1461
93. Höppener JW, Verbeek JS, Koning EJ de, Oösterwijk C, Hulst KL van, Visser-Vernooy HJ, Hofhuis FM, Gaalen S van, Berends MJ, Hackeng WH, et al. (1993) Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia. Diabetologia 36:1258-1265
94. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:7283-7288
95. Höppener JWM, Oösterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JHH, Vroom TM, Ahrén B, Lips CJM (1999) Extensive islet amyloid formation is induced by development of type H diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:427-434
96. Soeller WC, Janson J, Hart SE, Parker JC, Carty MD, Stevenson RW, Kreutter DK, Butler PC (1998) Islet amyloid-associated diabetes in obese A(vy)/ a mice expressing human islet amyloid polypeptide. Diabetes 47:743-750
97. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner Weir S, Baskin DG, Kahn SE (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492-3496
98. Geisler JG, Zawalich W, Zawalich K, Lakey JR, Stukenbrok H, Milici AJ, Soeller WC (2002) Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide. Diabetes 51:2158-2169
99. Hull RL, Verchere CB, Andrikopoulos S, Wang F, Vidal J, Kahn SE (2001) Oophorectomy promotes islet amyloid formation in human islet amyloid polypeptide transgenic mice islet. Diabetes 50 [Suppl 1]:S184-185
100. Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P (2000) Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med 6:998-1007
101. Ma Z, Westermark GT (2002) Effects of free fatty acid on polymerization of islet amyloid polypeptide (IAPP) in vitro and on amyloid fibril formation in cultivated isolated islets of transgenic mice overexpressing human IAPP. Mol Med 8:863-868
102. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M, Prigeon RL, Kahn SE (2003) Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52:372-379
103. Vidal J, Verchere CB, Andrikopoulos S, Wang F, Hull RL, Cnop M, Olin KL, LeBoeuf RC, O'Brien KD, Chait A, Kahn SE (2003) The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Diabetologia 46:71-79
104. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289
105. MacArthur DLA, Koning EJP de, Verbeek JS, Morris JE, Clark A (1999) Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets. Diabetologia 42:1219-1227
106. Carlsson P-O, Jansson L, Ostenson C-G, Kallskog O (1997) Islet capillary blood pressure increase mediated by hyperglycaemia in NIDDM GK rats. Diabetes 46:947-952
107. Schnell AH, Swenne I, Borg LAH (1988) Lysosomes and pancreatic islet function: a quantitative estimation of crinophagy in the mouse pnacreatic beta cell. Cell Tissue Res. 252:9-15
108. Clark A, Edwards CA, Ostle LR, Sutton R, Rothbard JB, Morris JF, Turner RC (1989) Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human beta-cells and in islets of type-2 diabetic subjects. Cell Tissue Res 257:179-185
109. Koning EJ de, Höppener JW, Verbeek JS, Oösterwijk C, Hulst KL van, Baker CA, Lips CJ, Morris JF, Clark A (1994) Human islet amyloid polypeptide accumulates at similar sites in islets of transgenic mice and humans. Diabetes 43:640-644
110. Pepys MB (2001) Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci 356:203-210
111. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3:855-859
112. Badman MK, Pryce RA, Charge SB, Morris JF, Clark A (1998) Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation. Cell Tissue Res 291:285-294
113. Koning EJ de, Brand JJ van den, Mott VL, Chargé SB, Hansen BC, Bodkin NL, Morris JF, Clark A (1998) Macrophages and pancreatic islet amyloidosis. Amyloid 5:247-254
114. Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514-2520
115. Caughey B, Lansbury PT Jr (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267-298
116. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491-498
117. Scrocchi LA, Ha K, Chen Y, Wu L, Wang F, Fraser PE (2003) Identification of minimal peptide sequences in the (8-20) domain of human islet amyloid polypeptide involved in fibrillogenesis. J Struct Biol 141:218-227
118. Mirzabekov T, Lin M, Kagan B (1996) Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 271:1988-1992
119. Wagoner PK, Chen C, Worley JF, Dukes ID, Oxford GS (1993) Amylin modulates beta-cell glucose sensing via effects on stimulus-secretion coupling. Proc Natl Acad Sci USA 90:9145-9149
120. Saafi EL, Konarkowska B, Zhang S, Kistler J, Cooper GJ (2001) Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet beta-cells. Cell Biol Int 25:339-350
121. Harroun TA, Bradshaw JP, Ashley RH (2001) Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett 507:200-204
122. Anguiano M, Nowak RJ, Lansbury PT Jr (2002) Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41:11338-11343
123. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110
124. Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B (2000) Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes 49:1325-1333
125. Jarrett JT, Lansbury PT Jr (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-1058
126. Hoenig M, Hall G, Ferguson F, Jordan K, Henderson M, Johnson K, O'Brien T (2000) A feline model of experimentally induced amyloidosis. Am J Pathol 157:2143-2150
127. UKPDS (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
128. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4:822-826
129. Scrocchi LA, Chen Y, Waschuk S, Wang F, Cheung S, Darabie AA, McLaurin J, Fraser PE (2002) Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. J Mol Biol 318:697-706